Skip to main content

Table 2 Treatment status after first antipsychotic prescription fill and time to discontinuation of overall antipsychotic therapy

From: Low continuation of antipsychotic therapy in Parkinson disease – intolerance, ineffectiveness, or inertia?

  Pimavanserin
(n = 153)
Quetiapine
(n = 2452)
Aripiprazole
(n = 169)
Risperidone
(n = 462)
Olanzapine
(n = 304)
p-value
Treatment status after first AP prescription fill
 Discontinued overall AP therapy, n (col%) 35 (22.9) 960 (39.2) 69 (40.8) 195 (42.2) 111 (36.5) 0.0006a
 Continued overall AP therapy, n (col%) 118 (77.1) 1492 (60.8) 100 (59.2) 267 (57.8) 193 (63.5)  
  Continued initial AP medication 105 (68.6) 1369 (55.8) 92 (54.4) 225 (48.7) 161 (53.0) 0.0005a
  Switched to another AP medication 13 (8.5) 123 (5.0) 8 (4.7) 42 (9.1) 32 (10.5) < 0.0001a
 Median time to discontinuation of overall AP therapy, days (IQR) 168 (71–213) 96.5 (44–203) 85 (44–190) 72 (44–186) 78 (44–193.5) < 0.0001b
 Average supply of initial AP Rx, days (SD) 32.8 (12.6) 35.8 (19.8) 37.6 (22.2) 32.0 (15.5) 33.7 (19.4) 0.0007b
  1. AP antipsychotic, IQR interquartile range, Rx prescription, SD standard deviation
  2. a Chi-square for categorical variables; b Kruskal-Wallis for continuous variables